@OncLiveSOSS profile picture
OncLive SOSS @OncLiveSOSS

Premier oncology summits that focus on the most relevant cancer topics to ultimately improve patient care. #OncLiveIPC

Joined January 2017
  • Tweets 25,051
  • Following 708
  • Followers 2,511
8,966 Photos and videos
Don't worry! To continue to see live updates from our premier oncology-focused cancer care summits, follow us at @OncLive.
1
789
Manali Bhave, MD, of @WinshipAtEmory, discusses the impact of new treatment strategies on the landscape of hormone receptor–positive/HER2-negative breast cancer. #bcsm ow.ly/IXo250OVckX
1
1
916
Brian I. Rini, MD, FASCO, @VUMC_Cancer, discusses efforts to utilize genetic testing to improve treatment selection in renal cell carcinoma through the phase 2 OPTIC RCC trial. #kcsm ow.ly/9eip50OVcem

Dr Rini on the OPTIC RCC Trial in Advanced Kidney Cancer | OncLive

Brian I. Rini, MD, FASCO, discusses efforts to utilize genetic testing to improve treatment selection in renal cell carcinoma through the phase 2 OPTIC RCC trial.

onclive.com
454
Ernest S. Han, MD, PhD, of @cityofhope, discusses the use of hyperthermic intraperitoneal chemotherapy in ovarian cancer. #ovca ow.ly/mTnB50OVcjm
392
Stephen V. Liu, MD, of @LombardiCancer, highlights the importance of next-generation sequencing in lung cancer, key trials that have shifted the NSCLC treatment landscape, and detailed ongoing research at his institution. #lcsm ow.ly/CSIL50OUtuU

Investigators Set Sights on Immunotherapy for Long-Term Disease Control in NSCLC | OncLive

Stephen V. Liu, MD, highlighted the importance of next-generation sequencing in lung cancer, key trials that have shifted the non–small cell lung cancer treatment landscape, and detailed ongoing...

onclive.com
1
320
Anne M. Noonan, MBBCh, @OSUCCC_James, discusses recent practice-changing trials for the treatment of patients with hepatocellular carcinoma. #hcc #oncology ow.ly/uev450OVch3
302
John L. Hays, MD, PhD, @OSUCCC_James, discusses the evolution of the treatment paradigm for patients with metastatic colorectal cancer who experience disease progression following standard chemotherapy regimens. #crcsm ow.ly/GgE250OVcc0

Dr Hays on the Evolution of Later-line Treatment Options in Refractory mCRC | OncLive

John L. Hays, MD, PhD, discusses the evolution of the treatment paradigm for patients with metastatic colorectal cancer who experience disease progression following standard chemotherapy regimens.

onclive.com
242
Several landmark trials have led to FDA approval milestones across all breast cancer subtypes in the past 5 years, each continuing to change the navigation of treatment approaches in clinical practice. @SitemanCenter #bcsm ow.ly/Ft5s50OUtQ8
247
Marilyn Huang, MD, @SylvesterCancer, contextualizes findings within the endometrial cancer treatment landscape and emphasizes the unanswered questions regarding optimal therapies for patients with mismatch repair–proficient disease. #gynsm ow.ly/vmT050OUtPQ
1
1
477
Edgardo S. Santos, MD, FACP, @FAUMedSchool, discusses the impact of treatment with cemiplimab plus chemotherapy in patients with squamous non–small cell lung cancer. #lcsm ow.ly/yxv050OUtte

Dr Santos on the Impact of Cemiplimab With Chemotherapy in Squamous NSCLC | OncLive

Edgardo S. Santos, MD, FACP, discusses the impact of treatment with cemiplimab plus chemotherapy in patients with squamous non–small cell lung cancer.

onclive.com
237
Foluso Bisi Ademuyiwa, MD, MPH, MSCI, of @SitemanCenter, discusses the optimal sequencing of current CDK4/6 inhibitors in the first-line setting for hormone receptor–positive, HER2-negative breast cancer based on updated efficacy and safety data. #bcsm ow.ly/AaRT50OUtAW
195
Stephanie L. Graff, MD, of @LifespanHlthSys, gives an overview of recently approved ADCs in TNBC and HR-positive, HER2-negative breast cancer and the importance of continued research with these agents in the first-line setting. #bcsm ow.ly/slyF50OUtyV
1
3
395
Christie J. Hilton, DO, @alleghenyhealth discusses the potential impact of the ongoing phase 2 CompassHER2-pCR trial for patients with HER2-positive breast cancer. #bcsm ow.ly/WMjp50OUtsw

Dr Hilton on the Potential Impact of the CompassHER2-pCR Trial in HER2 Breast Cancer | OncLive

Christie J. Hilton, DO, discusses the potential impact of the ongoing phase 2 CompassHER2-pCR trial for patients with HER2-positive breast cancer.

onclive.com
179
Foluso Bisi Ademuyiwa, MD, MPH, MSCI, of @SitemanCenter, discusses the implications of the phase 3 KEYNOTE-522 trial in high-risk, early-stage triple-negative breast cancer. #bcsm ow.ly/xrHB50OTa4q
264
Stephen V. Liu, MD, of @LombardiCancer, discusses the activity of trastuzumab deruxtecan in patients with HER2-mutated non–small cell lung cancer. #lcsm ow.ly/1jcE50OT9ZT
1
232
Bradley W. Christensen, MD, of @bswhealth, discusses the process of patient selection for BCL-2 induction therapy in patients with acute myeloid leukemia in accordance with their individual disease characteristics. #leusm ow.ly/X4TX50OT9XQ
189
Colin E. Champ, MD, of @alleghenyhealth, discusses findings from 2 clinical trials investigating boost radiotherapy plus whole breast radiotherapy following surgery in patients with ductal carcinoma in situ or early-stage breast cancer. #bcsm ow.ly/KRzF50OTapv

Dr Champ on Boost Radiotherapy in Breast Cancer | OncLive

Colin E. Champ, MD, discusses findings from 2 clinical trials investigating boost radiotherapy plus whole breast radiotherapy following surgery in patients with ductal carcinoma in situ or early-st...

onclive.com
165
Jeffrey Zonder, MD, of @karmanoscancer, discusses the ongoing development of other BCMA-targeted and non–BCMA targeted bispecific antibodies in multiple myeloma, and how to navigate treatment decisions for patients eligible for CAR T-cell therapy. #mmsm ow.ly/JcIA50OTa91
201
Claire F. Verschraegen, MD, @OSUCCC_James, discusses adverse effects that are commonly associated with the use of single-agent nivolumab vs the combination of ipilimumab plus nivolumab in melanoma. #melsm ow.ly/6nw050OT9WJ
147
Eunice Wang, MD, of @RoswellPark, discusses how the continued development of targeted therapies could improve the future treatment paradigm in acute myeloid leukemia. #leusm ow.ly/a6F350OTala

Dr Wang on the Future of Targeted Therapies in AML | OncLive

Eunice Wang, MD, discusses how the continued development of targeted therapies could improve the future treatment paradigm in acute myeloid leukemia.

onclive.com
1
521
Load more